Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solcera vs Placebo and Solaraze in Actinic Keratosis (KOHDIAK)
NCT04552327Phase 3Completed
- Sponsor
- InfectoPharm
- Start
- Oct 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of potassium hydroxide in actinic keratosis (AK) (3 arms), sponsored by InfectoPharm. Primary endpoint: Treatment success. Started Oct 2020; status: completed.
02
Drugs
potassium hydroxide
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT04552327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552327.